Identification of New Inhibitors for Human SIRT1: An in-silico Approach

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Structural Biology

Background:

• Human SIRT1 (silent information regulator 1) is a class III histone deacetylase (HDAC) implicated in cancer development.
• Inhibiting hSIRT1's deacetylase function presents a potential therapeutic strategy for cancer treatment.
• A scarcity of effective hSIRT1 inhibitors necessitates the identification of novel, high-efficacy compounds.

Purpose of the Study:

• To discover novel inhibitor compounds targeting the human SIRT1 protein using a rational, structure-based drug design approach.
• To identify new chemical scaffolds with potential hSIRT1 inhibitory activity.

Main Methods:

• Structure-based virtual screening of the DrugBank library against the hSIRT1 HDAC domain using AutoDock Vina.
• Molecular docking studies utilizing the crystal structure of the hSIRT1 HDAC domain (PDB ID: 4KXQ).
• Molecular dynamics simulations and in vitro deacetylase assays to validate compound binding and inhibitory activity.

Main Results:

• Virtual screening identified seven compounds belonging to diphenyl and oxycoumarin derivative classes.
• Molecular dynamics simulations confirmed stable binding of the seven selected compounds to hSIRT1.
• Four commercially available drugs containing these scaffolds demonstrated significant inhibition of hSIRT1 deacetylase activity compared to sirtinol.

Conclusions:

• Diphenyl and oxycoumarin derivatives show potential as effective inhibitors of human SIRT1.
• These compound series represent promising scaffolds for developing new chemical libraries targeting hSIRT1.
• The identified compounds warrant further investigation for their therapeutic potential in cancer treatment.